Boehringer Ingelheim is gearing up to take survodutide to regulators next year after the obesity drug proved its ...

Windward Bio is sailing toward the public markets with the aim of wafting in over $200 million in proceeds to fund two ...

Zura Bio’s tibulizumab has flunked a phase 2 hidradenitis suppurativa (HS) trial, prompting the biotech to end development in ...

Delix Therapeutics has raised $100 million in a series C round backed by the likes of Johnson & Johnson to advance a phase ...

Spruce Biosciences is spinning out a preclinical endocrinology program to be led by a newly formed subsidiary called Adrenyx ...

Vir Biotechnology’s phase 3 trial in chronic hepatitis delta (CHD) has hit its primary endpoint, giving the biopharma the ...

Kyorin Pharmaceutical is paying $12 million upfront for the Japan rights to Edesa Biotech’s late-stage anti-TLR4 antibody to ...

Faeth Therapeutics’ endometrial cancer prospect has cleared the phase 2 efficacy bar, emboldening the biotech to forge ahead ...

For translational and clinical development leaders, the takeaway is actionable: evaluate genotype as a trial-design variable.

Argenx has struck a deal to acquire Unnatural Products (UNP) for $550 million upfront, snapping up the Merck & Co.- and ...

Fernandes, Executive Vice President, Chief Business Officer at Ipsen | Science rarely moves in a straight line. Philippe Lopes-Fernandes explores how an unexpected turn can reveal a credible path to ...

Novartis has lifted the lid on data from its failed cardiovascular outcomes trial, reporting a total absence of efficacy that ...